JAK2 and acquired polycythemia vera: The findings, together with the arguments that PV is driven by neoplastic cells carrying JAK2 mutations regardless of the risk category, suggest that the removal of neoplastic cells, even in low-risk PV, is likely to be beneficial [53, 65].